Back to Results
First PageMeta Content
Diols / Expectorants / Guaifenesin / Uric acid / Combination drugs / Uricosuric / Food and Drug Administration / Cough medicine / Fibromyalgia / Medicine / Pharmacology / Health


Document Date: 2004-01-06 18:55:55

Open Document

File Size: 847,67 KB

Share Result on Facebook

Company

Postlethwaite AE / Guai-Support Group / Adams Laboratories / Adams Labs / X2003 Adams Labs / Support Group Network Kathleen Shuller Guai-Support / /

Country

Afghanistan / Canada / /

Event

FDA Phase / Patent Issuance / /

IndustryTerm

immediate-release products / law change / false and misleading advertising / pharmaceutical industry / guaifenesin products / treatment of chronic disease / manufacturing rights / bi-iayer technology / insurance coverage / manufacturing industry / sustained-release guaifenesin product / nonsugar based product / guaifenesin protocol / treatment of acute respiratory disease / recent law changes / sustained-release product / drug manufacturing industry / sustained-release guaifenesin products / justified removing all sustained-release guaifenesin products / /

MedicalCondition

acute respiratory disease / Fibromyalgia / bronchitis / lung disorders / A.I.D.S. Pneumonia / respiratory irritation / gout / fellow fibromyalgia sufferers / common lung infections / cystic fibrosis / chronic bronchitis / asthma / infertility / disease / Untreated disease / very serious diseases / diabetes / chronic lung disease / chronic disease / diseases / respiratory disease / /

Organization

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration / Congress / FDA / Department of Defense / /

Person

R. Paul St. Amand / /

Position

attorney / attorney for further legal action / Representative Panama City Fi The +gnatofylsignatories / /

Product

Mucinex / Social Security System / Cuaifenesin syrup / /

Technology

bi-iayer technology / guaifenesin protocol / http / /

URL

http /

SocialTag